ResMed director sells 2,000 shares under 10b5-1

ResMed Inc. director Peter C. Farrell sold 2,000 shares of ResMed Common Stock in an open-market transaction.

(Neutral)

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

ResMed Inc. director Peter C. Farrell sold 2,000 shares of ResMed Common Stock in an open-market transaction. The sale occurred on March 4, 2026 at an average price of $260.22 per share. After this trade, he directly owned 62,773 shares. The transaction was conducted under a Rule 10b5-1 trading plan adopted on August 12, 2025.

Insider Trade Summary

Net Seller: 2,000 shares

Net Sell 1 txn

Insider FARRELL PETER C

Role Director

Sold 2,000 shs ($520K)

Type	Security	Shares	Price	Value
Sale	ResMed Common Stock	2,000	$260.22	$520K

Holdings After Transaction: ResMed Common Stock — 62,773 shares (Direct)

Footnotes (1)

F1. The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ResMed (RMD) director Peter C. Farrell report in this Form 4 filing?

Peter C. Farrell reported an open-market sale of 2,000 ResMed Common Stock shares. The transaction occurred on March 4, 2026, at an average price of $260.22 per share, and was executed under a previously adopted Rule 10b5-1 trading plan.

How many ResMed (RMD) shares did Peter C. Farrell sell and at what price?

Peter C. Farrell sold 2,000 shares of ResMed Common Stock. The reported average sale price was $260.22 per share on March 4, 2026, reflecting an open-market or private transaction as classified in the insider trading report.

How many ResMed (RMD) shares does Peter C. Farrell hold after this transaction?

After the reported sale, Peter C. Farrell directly holds 62,773 shares of ResMed Common Stock. This post-transaction balance reflects his remaining direct ownership as disclosed in the Form 4 insider trading report filed for the March 4, 2026 transaction.

Was the ResMed (RMD) insider sale by Peter C. Farrell under a Rule 10b5-1 plan?

Yes. The filing states the transaction was conducted under a Rule 10b5-1 trading plan adopted on August 12, 2025. Such plans allow pre-arranged trading according to preset instructions, helping separate routine portfolio moves from discretionary timing decisions.

What transaction code is used in Peter C. Farrell’s ResMed (RMD) Form 4 filing?

The Form 4 uses transaction code “S,” indicating a sale in an open market or private transaction. The report further describes the action as an open-market sale of non-derivative ResMed Common Stock on March 4, 2026, at $260.22 per share.

Is Peter C. Farrell’s ownership in ResMed (RMD) direct or indirect after this sale?

The filing classifies his ownership as direct, using the code “D” for the reported holdings. After selling 2,000 shares, his direct ownership stands at 62,773 ResMed Common Stock shares, with no additional nature-of-ownership entities described in the transaction details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/05/2026 - 02:51 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FARRELL PETER C

(Last)

(First)

(Middle)

9001 SPECTRUM CENTER BLVD.

(Street)

SAN DIEGO

92123

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
ResMed Common Stock	03/04/2026		S⁽¹⁾		2,000	D	$260.22	62,773	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025.

	/s/ Peter C. Farrell, Chairman emeritus	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR